

Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping the September 30 approval date on schedule.
You can purchase shares of Scholar Rock Holding (NASDAQ:SRRK) through any online brokerage.
Other companies in Scholar Rock Holding’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Scholar Rock Holding has a consensus price target of $63.18.
The stock price for Scholar Rock Holding (NASDAQ: SRRK) is $41.14 last updated October 23, 2026 at 2:40 PM EDT.
There are no upcoming dividends for Scholar Rock Holding.
Scholar Rock Holding does not have any upcoming earnings scheduled.
There is no upcoming split for Scholar Rock Holding.
Scholar Rock Holding is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab...